Resources
Publications
Publications
This paper by scientists at Merck KGaA describes generation, identification and evaluation of a major oxidised metabolite of xevinapant in which Hypha later generated the reference standard using microbial biotransformation.
This paper on generation of an indirect N-glucuronide of Camizestrant features a new approach to synthesizing glucuronides of compounds with acidic functional groups that interfere with their susceptibility to glucuronidation.
Joint paper published by scientists at Hypha Discovery and the Dundee Drug Discovery Unit on use of PolyCYPs enzymes for late-stage functionalization of biologically relevant compounds active against a range of pathogens.
This joint paper by scientists at Janssen and Hypha describes biosynthesis and structure assignment of a major hydroxylated metabolite of the orexin-1 receptor antagonist JNJ-61393215. PolyCYPs enzymes were instrumental in achieving synthesis of gram amounts of the metabolite.
This joint paper published by scientists at Repare Therapeutics, BioAgilytix and Hypha Discovery is the first report of a N-glucuronide metabolite of camonsertib formed in human hepatocyte incubations. The structure of the metabolite was elucidated by NMR after scale-up using microbial biotransformation to produce the N-glucuronide.
In this open access review in Drug Discovery Today we look at the why, when and how metabolites of small-molecule drugs are synthesised from the perspective of a specialist CRO.
Stay up to date with the latest news from Hypha Discovery
Sign up for our quarterly newsletters and monthly "Metabolite Tales" blog
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.